Premedication for Neonatal Respiratory Distress Syndrome
(PRELISA Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial investigates whether administering a combination of two medicines, IV atropine and IV fentanyl, to preterm infants before a procedure called Less Invasive Surfactant Administration (LISA) can enhance safety and effectiveness. The researchers aim to determine if these medicines can reduce incidents of low heart rate and low oxygen levels during LISA, improve the procedure's success rate, and influence the need for additional breathing support. Babies born at 29 weeks or later, who are on CPAP (a type of gentle breathing support) and require extra oxygen, may be suitable for this study. Participants will be randomly assigned to receive either the medication or a placebo (a harmless substance with no active ingredients) before the procedure. As a Phase 4 trial, this study involves an FDA-approved treatment and seeks to understand how it can benefit more patients.
Will I have to stop taking my current medications?
The trial information does not specify whether participants must stop taking their current medications.
What is the safety track record for IV atropine and fentanyl premedication?
Research has shown that a combination of IV atropine and fentanyl is generally safe for infants. In past studies, when newborns received fentanyl nasally for procedures like intubation, no negative effects occurred. This suggests that fentanyl, when administered in controlled amounts, is safe for infants.
Fentanyl has also been used in premature infants needing assistance with breathing due to respiratory distress syndrome. Research indicates it does not cause long-term problems. Atropine, often used to control heart rate during procedures, has a strong safety record in other medical contexts.
Since this trial is in a later phase, there is already a strong understanding of the safety of these medications in similar situations. This suggests that infants in the study are likely to tolerate the treatment well.12345Why are researchers enthusiastic about this study treatment?
Most treatments for neonatal respiratory distress syndrome (RDS) involve surfactant therapy or mechanical ventilation to help newborns breathe. But the combination of IV atropine and fentanyl offers a unique approach as a premedication regimen before a less invasive surfactant administration (LISA) procedure. Atropine is used to reduce secretions and prevent bradycardia, while fentanyl provides pain relief, making the procedure smoother and more comfortable for the infant. Researchers are excited because this combination could reduce the stress and potential complications associated with traditional methods, potentially leading to better outcomes for these vulnerable patients.
What evidence suggests that this premedication is effective for neonatal respiratory distress syndrome?
Research has shown that administering IV atropine and fentanyl before the Less Invasive Surfactant Administration (LISA) procedure in premature babies can reduce the risk of slow heart rate and low oxygen levels. In this trial, some participants will receive this combination as premedication. Studies with newborns have found that fentanyl does not cause harmful effects, indicating its safety. Atropine, when combined with fentanyl, helps maintain steady heart rate and blood pressure during the procedure. These medications are believed to increase the likelihood of a successful first attempt. Overall, this combination is thought to enhance the safety and effectiveness of the procedure for babies with breathing problems.12467
Who Is on the Research Team?
Venkatakrishna Kakkilaya, MD
Principal Investigator
UT Southwestern Medical Center
Are You a Good Fit for This Trial?
The PRELISA trial is for preterm infants aged between 0-72 hours, at least 29 weeks gestational age, needing CPAP respiratory support and qualifying for the LISA procedure. It excludes those with severe congenital anomalies, born to mothers with opioid addiction or on methadone treatment, or requiring intubation before surfactant therapy.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either IV atropine and fentanyl or placebo prior to the Less Invasive Surfactant Administration (LISA) procedure
Observation
Participants are monitored for bradycardia and hypoxemia events during and immediately after the LISA procedure
Follow-up
Participants are monitored for safety and effectiveness, including intubation rates and cerebral oxygenation, after the procedure
What Are the Treatments Tested in This Trial?
Interventions
- IV Atropine and Fentanyl
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Texas Southwestern Medical Center
Lead Sponsor
Chiesi Farmaceutici S.p.A.
Industry Sponsor